These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17958766)

  • 1. Estimating the economic burden of inflammatory bowel disease in Canada: physician office visits and mesalamine prescriptions dispensed as surrogate markers.
    Wong VK; Lee TK; Yoshida EM
    Am J Gastroenterol; 2007 Nov; 102(11):2602-3; author reply 2603-4. PubMed ID: 17958766
    [No Abstract]   [Full Text] [Related]  

  • 2. The epidemiology of inflammatory bowel disease in Canada: a population-based study.
    Bernstein CN; Wajda A; Svenson LW; MacKenzie A; Koehoorn M; Jackson M; Fedorak R; Israel D; Blanchard JF
    Am J Gastroenterol; 2006 Jul; 101(7):1559-68. PubMed ID: 16863561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in inflammatory bowel disease: are patients taking their medicines? Interview by Paul C. Adams.
    Ghosh S
    Can J Gastroenterol; 2009 Jan; 23(1):13-4. PubMed ID: 19172201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-ASA therapy and renal function in inflammatory bowel disease.
    Siveke JT; Egert J; Sitter T; Schiemann U; Walcher P; Török HP; Glas J; Folwaczny C
    Am J Gastroenterol; 2005 Feb; 100(2):501. PubMed ID: 15667517
    [No Abstract]   [Full Text] [Related]  

  • 5. Thorax as an extraintestinal target for inflammatory bowel disease.
    Akpınar EE; Gülhan M; Değertekin H; Ataoğlu Ö
    Tuberk Toraks; 2011; 59(3):312-5. PubMed ID: 22087529
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Butterworth JR
    Dig Liver Dis; 2009 May; 41(5):338-9. PubMed ID: 19268635
    [No Abstract]   [Full Text] [Related]  

  • 7. [Epidemiology and risk factors of inflammatory bowel diseases].
    Colombel JF; Vernier-Massouille G; Cortot A; Gower-Rousseau C; Salomez JL
    Bull Acad Natl Med; 2007 Jun; 191(6):1105-18; discussion 1118-23. PubMed ID: 18402167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of high doses of mesalazine during pregnancy.
    Marteau P; Seksik P; Couve S; Jian R
    Am J Gastroenterol; 2005 Aug; 100(8):1897-8. PubMed ID: 16086733
    [No Abstract]   [Full Text] [Related]  

  • 9. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data.
    Benchimol EI; Guttmann A; Griffiths AM; Rabeneck L; Mack DR; Brill H; Howard J; Guan J; To T
    Gut; 2009 Nov; 58(11):1490-7. PubMed ID: 19651626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macroscopic and histopathological examination of the gastric mucosa in dogs with inflammatory bowel disease (IBD) treated with mesalazine.
    Rychlik A; Nieradka R; Kander M; Depta A
    Pol J Vet Sci; 2009; 12(2):217-23. PubMed ID: 19645352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesalazine. Now authorised for children, but no suitable form.
    Prescrire Int; 2011 Sep; 20(119):208. PubMed ID: 21954515
    [No Abstract]   [Full Text] [Related]  

  • 13. [Side effects of 5-aminosalicylic acid].
    Marteau P; Cellier C
    Gastroenterol Clin Biol; 1997; 21(5):377-86. PubMed ID: 9208013
    [No Abstract]   [Full Text] [Related]  

  • 14. Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy.
    Sari I; Birlik M; Cavdar C; Sarioglu S; Akpinar H; Onen F; Akkoc N
    N Z Med J; 2005 Sep; 118(1222):U1662. PubMed ID: 16222356
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidemiology of toxic nephropathies.
    Elseviers MM; De Broe ME
    Adv Nephrol Necker Hosp; 1997; 27():241-62. PubMed ID: 9408450
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia.
    Staatz CE; Martin NS; Kong DP; Hollingworth SA
    Dig Liver Dis; 2018 Mar; 50(3):314-317. PubMed ID: 29311026
    [No Abstract]   [Full Text] [Related]  

  • 17. Onychomycosis in inflammatory bowel diseases.
    Gaburri D; Chebli JM; Zanine A; Gamonal AC; Gaburri PD
    J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):807-12. PubMed ID: 18435735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The problems of compliance and adherence, using the example of chronic inflammatory bowel disease].
    Zimmerer T; Siegmund SV; Singer MV
    Dtsch Med Wochenschr; 2009 Jul; 134(27):1417-24. PubMed ID: 19551607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of inflammatory bowel disease 'beyond the West': do prosperity and improved hygiene have a role?
    de Silva HJ; de Silva NR; de Silva AP; Jewell DP
    Trans R Soc Trop Med Hyg; 2008 Sep; 102(9):857-60. PubMed ID: 18455744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.